Amgen (AMGN) Short-term Investments (2009 - 2023)

Amgen's Short-term Investments history runs 15 years deep, the most recent figure standing at $1.0 million for Q1 2023.

• In Q1 2023, Short-term Investments fell 93.75% year-over-year to $1.0 million; the TTM figure through Mar 2023 stood at $1.0 million (down 93.75% YoY), while the FY2022 annual figure was $1.7 billion, up 3391.67% from the prior year.
• Short-term Investments for Q1 2023 stood at $1.0 million, down from $1.7 billion in the prior quarter.
• The five-year high for Short-term Investments was $18.9 billion in Q1 2019, with the low at $1.0 million in Q1 2023.
• The 5-year median for Short-term Investments is $2.0 billion (2022), against an average of $4.1 billion.
• Peak annual rise in Short-term Investments reached 3391.67% in 2022, while the deepest fall reached 99.64% in 2022.
• Amgen's Short-term Investments stood at $2.9 billion in 2019, then surged by 52.44% to $4.4 billion in 2020, then tumbled by 98.9% to $48.0 million in 2021, then jumped by 3391.67% to $1.7 billion in 2022, then slumped by 99.94% to $1.0 million in 2023.
• Business Quant data shows AMGN's Short-term Investments at $1.0 million in Q1 2023, $1.7 billion in Q4 2022, and $2.0 billion in Q3 2022.